Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegideridine vs morphine for postoperative analgesia after laparoscopic colorectal cancer resection
ChiCTR2600125316Phase 4Not yet recruiting
- Sponsor
- Quzhou People's Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tegileridine in colorectal cancer (CRC) (2 arms), sponsored by Quzhou People's Hospital. Primary endpoint: Resting Sum of Pain Intensity Difference in 48 hours (rSPID48). Planned start May 2026; status: not yet recruiting.
02
Drugs
tegileridine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600125316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125316.